Neogenomics (NEO) Enterprise Value (2010 - 2026)

Neogenomics has reported Enterprise Value for 17 years, with the latest figure at -$146.1 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 59.19% year-over-year to -$146.1 million; the trailing twelve-month figure through Mar 2026 stood at -$146.1 million (up 59.19% YoY), and the FY2025 full-year result was -$159.6 million, up 58.74% from the prior year.
• Enterprise Value for Q1 2026 stood at -$146.1 million, up from -$159.6 million in the prior quarter.
• The five-year high for Enterprise Value was -$146.1 million in Q1 2026, with the low at -$481.4 million in Q1 2022.
• Historically, Enterprise Value has averaged -$353.7 million across 5 years, with a median of -$387.9 million in 2024.
• Annual changes were most pronounced in 2024 — Enterprise Value climbed 3.59% — and 2026, when it jumped 59.19%.
• Neogenomics' Enterprise Value stood at -$438.0 million in 2022, then gained by 5.2% to -$415.2 million in 2023, then increased by 6.83% to -$386.8 million in 2024, then surged by 58.74% to -$159.6 million in 2025, then advanced by 8.44% to -$146.1 million in 2026.
• The last three Enterprise Value figures came in at -$146.1 million (Q1 2026), -$159.6 million (Q4 2025), and -$164.1 million (Q3 2025), per Business Quant data.